New covid vaccine vs standard shot after stem cell transplant
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new type of COVID-19 vaccine (called LUNAR-COV19) designed to boost your immune system, compared to the standard Pfizer vaccine (Comirnaty), specifically for people who recently had a stem cell transplant. The hope is that the new vaccine gives stronger and longer-lasting protection against COVID-19.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You received a stem cell transplant from a donor within the past year.
- You have not had a relapse or progression of your cancer since the transplant.
- You have not had COVID-19 or a COVID infection in the last 28 days.
- You are not currently on a high dose of steroids (more than 1 mg/kg per day) or certain immune-suppressing treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a vaccine designed to boost immunity against CMV (a common virus) and prevent active CMV infection in people receiving a half-matched stem cell transplant. It may help protect you from CMV-related complications after transplant.
This Phase 1 trial tests a donated immune-cell treatment (T cells) to help immunocompromised people fight or resist COVID-19 after they recently received a bone marrow or stem cell transplant. It aims to see if the treatment is safe and if it helps the body respond better to the virus.
This trial is for people with high-risk acute lymphoblastic leukemia who are getting a stem cell transplant from a family donor. After transplant, you'd receive a treatment that combines specially designed immune cells (CAR T cells) that target your leukemia, plus a vaccine that helps those cells work better.
This trial studies a vaccine designed to help the body fight cytomegalovirus (CMV) in children who test positive for CMV and are about to receive a donor stem cell transplant. If it works, it may reduce CMV-related illness during recovery after transplant.
This trial tests whether giving a CMV vaccine to stem cell donors can help protect recipients from CMV infection after transplant. It is for adults with specific blood cancers who are CMV-positive and have a matched related donor.
This trial tests two RSV vaccine schedules in people who have had a lung transplant or a stem cell transplant. It looks at whether the vaccines are safe and how well they boost the immune system against RSV, a common respiratory virus.
Hear when a new Hematopoietic and Lymphatic System Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.